These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21290407)

  • 1. γ-Aminobutyric acid type B receptor changes in the rat striatum and substantia nigra following intrastriatal quinolinic acid lesions.
    Rekik L; Daguin-Nerrière V; Petit JY; Brachet P
    J Neurosci Res; 2011 Apr; 89(4):524-35. PubMed ID: 21290407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes.
    Brickell KL; Nicholson LF; Waldvogel HJ; Faull RL
    J Chem Neuroanat; 1999 Oct; 17(2):75-97. PubMed ID: 10585160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GABA and GABAA receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease.
    Nicholson LF; Faull RL; Waldvogel HJ; Dragunow M
    Neuroscience; 1995 Jun; 66(3):507-21. PubMed ID: 7644016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential role of GABAA and GABAB receptors in two distinct output stations of the rat striatum: studies on the substantia nigra pars reticulata and the globus pallidus.
    Ikeda H; Kotani A; Koshikawa N; Cools AR
    Neuroscience; 2010 Apr; 167(1):31-9. PubMed ID: 20132872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
    Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
    Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time- and dose-dependent 45Ca2+ accumulation in rat striatum and substantia nigra after an intrastriatal injection of quinolinic acid.
    Gramsbergen JB; van der Sluijs-Gelling AJ
    Exp Neurol; 1993 Jun; 121(2):261-9. PubMed ID: 8339777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
    Ghorayeb I; Puschban Z; Fernagut PO; Scherfler C; Rouland R; Wenning GK; Tison F
    Exp Neurol; 2001 Jan; 167(1):133-47. PubMed ID: 11161601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of immunoreactivity for glial fibrillary acidic protein (GFAP) in astrocytes as a marker for profound tissue damage in substantia nigra and basal cortical areas after status epilepticus induced by pilocarpine in rat.
    Schmidt-Kastner R; Ingvar M
    Glia; 1994 Nov; 12(3):165-72. PubMed ID: 7851985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Enna SJ; Reisman SA; Stanford JA
    Neurosci Lett; 2006 Oct; 406(1-2):102-6. PubMed ID: 16890350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subpopulations of neurons in rat substantia nigra display GABA(B)R2 receptor immunoreactivity.
    Ng TK; Yung KK
    Brain Res; 2001 Nov; 920(1-2):210-6. PubMed ID: 11716827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
    Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
    Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
    Olds ME; Jacques DB; Kopyov O
    Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The subcellular localization of GABA(B) receptor subunits in the rat substantia nigra.
    Boyes J; Bolam JP
    Eur J Neurosci; 2003 Dec; 18(12):3279-93. PubMed ID: 14686901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
    Rite I; Machado A; Cano J; Venero JL
    Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.